OCGN Ocugen
- 1.3300
- +0.0100+0.76%
- 1.3400
- +0.0100+0.75%
Ocugen News
Ocugen | EFFECT: Others
Ocugen | 10-K/A: Annual report (Amendment)
Ocugen | 8-K: Current report
Ocugen | S-3: Registration statement for specified transactions by certain issuers
Ocugen | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Ocugen | 4: Statement of changes in beneficial ownership of securities-Officer Qamar Huma
Ocugen | 10-K: Annual report
Ocugen | 8-K: Ocugen Announces U.S. Food and Drug Administration Approval of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
Ocugen | 8-K: Ocugen Reports Year End 2023 Financial Results and Provides Corporate Update
Ocugen | 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Ocugen | NT 10-K: Others
Ocugen | 8-K: United States Court of Appeals for the Third Circuit Affirmed the Decision of Consolidated Securities Class Action Lawsuit
Ocugen | 3: Initial statement of beneficial ownership of securities-Officer Qamar Huma
Ocugen | 3: Initial statement of beneficial ownership of securities-Officer Breininger Michael
Ocugen | 8-K: Director Patrick Grady Will Not Run For Re-Election At The 2024 Shareholder Meeting
Ocugen | 8-K: Ocugen Announces Appointment of Huma Qamar as Chief Medical Officer
Ocugen | 8-K: Presentation of an In-Person Clinical Showcase at the Nasdaq Market Site in Times Square
Ocugen | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.69%)
Ocugen | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-STATE STREET CORPORATION(0.33%)
Ocugen | 8-K: Ocugen Grants Performance-Based Restricted Stock Units to Incentive Recipients
Analysis
Price Target
No Data
